RobertWesolowskiMD

Oncology • Columbus, OH

Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Join to view full profile

Dr. Wesolowski is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Wesolowski's full profile

Already have an account?

Office
460 W 10th Ave
Columbus, OH 43210
Phone+1 614-293-6529

Fax+1 614-293-9429

Education & Training

Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2007 - 2010
Cleveland Clinic FoundationResidency, Internal Medicine, 2004 - 2007
State University of New York Downstate Medical Center College of MedicineClass of 2004

Certifications & Licensure

OH State Medical License 2004 - 2025

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I Start of enrollment: 2011 Oct 01
Completed
Phase 4
Safety Study of PLX3397 and Paclitaxel in Patients With Advanced Solid Tumors Start of enrollment: 2012 May 01
Completed
Phase 1
AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Subjects With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy Start of enrollment: 2016 Apr 01
Completed
Phase 1, Phase 2
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors Start of enrollment: 2018 Jul 18
Completed
Phase 1
Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer Start of enrollment: 2019 Nov 14
Active, not recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2024-12-07
Baseline gut microbiome alpha diversity predicts chemotherapy-induced gastrointestinal symptoms in patients with breast cancer.
Lauren D Otto-Dobos, Lindsay D Strehle, Brett R Loman, Melina M Seng, Sagar D Sardesai
NPJ Breast Cancer. 2024-11-15
A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas.
Olivier Rixe, John L Villano, Robert Wesolowski, Anne M Noonan, Vinay K Puduvalli
Clinical Cancer Research. 2024-11-15

Journal Articles

Modeling Combination Therapy for Breast Cancer with BET and Immune Checkpoint Inhibitors
Robert Wesolowski, Andrew Stiff, Proceedings of the National Academy of Sciences

Press Mentions

Bexion Pharmaceuticals, Inc. Announces Publication of Phase 1 Data for BXQ-350 in Advanced Solid TumorsOctober 31st, 2024
Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
Sanofi’s, AstraZeneca’s and Radius’ Oral SERDs Could Establish Clinical Worth in ER+ Breast Cancer by Showing Similar Efficacy to Faslodex, Experts SayApril 6th, 2021
Join now to see all